Genetic overlap between estimated glomerular filtration rate and cardiovascular disease identifies potential targets for cardiorenal syndrome.
W, L., Y, C., W, X., & S, Y. (2026). Genetic overlap between estimated glomerular filtration rate and cardiovascular disease identifies potential targets for cardiorenal syndrome.. Renal failure. https://doi.org/10.1080/0886022X.2026.2721242
W L, Y C, W X, S Y. Genetic overlap between estimated glomerular filtration rate and cardiovascular disease identifies potential targets for cardiorenal syndrome.. Renal failure. 2026; doi: 10.1080/0886022X.2026.2721242
W L, Y C, W X, et al. Genetic overlap between estimated glomerular filtration rate and cardiovascular disease identifies potential targets for cardiorenal syndrome.[J]. Renal failure. 2026. DOI: 10.1080/0886022X.2026.2721242.
@article{w2026,
author = {Li W and Chen Y and Xiong W and Yuan S},
title = {Genetic overlap between estimated glomerular filtration rate and cardiovascular disease identifies potential targets for cardiorenal syndrome.},
journal = {Renal failure},
year = {2026},
doi = {10.1080/0886022X.2026.2721242},
note = {PMID: 42661344},
}
TY - JOUR AU - Li W AU - Chen Y AU - Xiong W AU - Yuan S TI - Genetic overlap between estimated glomerular filtration rate and cardiovascular disease identifies potential targets for cardiorenal syndrome. T2 - Renal failure PY - 2026 DO - 10.1080/0886022X.2026.2721242 AN - PMID:42661344 ER -
Heart and kidney diseases frequently coexist, but the genetic basis of this relationship remains unclear. We analyzed genetic data from large-scale studies to investigate how kidney function (estimated glomerular filtration rate, eGFR) and six common cardiovascular diseases share genetic risk factors. Using MiXeR method, and conjunctional false discovery rate (conjFDR) to identify overlapping genetic regions, we found 478 shared genomic loci between eGFR and cardiovascular diseases. These shared genes are involved in tissue development and structure. We also identified 29 genes that could be targeted by existing medications approved by the US Food and Drug Administration, such as PRKAG2, PDE1A, and IGF1R. Among these, genetically predicted higher level of IGF1R expression is associated with a higher eGFR, which reflects good kidney function and is protective against cardiorenal diseases, such as atrial fibrillation, and myocardial infarction. These findings reveal genetic overlap between kidney function and cardiovascular diseases, highlighting potential targets for understanding and treating cardiorenal syndrome.